RESEARCH ATLAS
← Compound index
COMPOUND RECORD / OLEYL-CORTAGEN

Oleyl-CortagenОлеил-кортаген

PerformanceStressRecovery
Source linked
01 / OVERVIEW

About Oleyl-Cortagen

Names in this research collection

Oleylcortagen · Oleyl-Ala-Glu-Asp-Pro · N-oleyl Cortagen

A lipid-modified Ala–Glu–Asp–Pro tetrapeptide evaluated in rat behavioral studies. Cortagen is the unmodified peptide and Cortexin is a separate tissue mixture.

Research background

A lipid-modified Ala–Glu–Asp–Pro tetrapeptide evaluated in rat behavioral studies. Cortagen is the unmodified peptide and Cortexin is a separate tissue mixture.

What the studies found

Animal research · 2015

Who or what was studied496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison

Reported finding

In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.

Oleyl-Cortagen · central self-stimulation
159.7±16.2 → 199.1±19.1 presses/5 min (+25%)p<0.05 before vs after at 1 µg1 µg into the ventricle; 10 and 100 µg produced +19% and +6% without significance marks.
Cortagen · central self-stimulation
208.0±26.7 → 270.4±26.4 presses/5 min (+30%)p<0.05 before vs after100 µg into the ventricle; lower doses lacked a significance mark.
Cortexin · central self-stimulation
209.3±22.9 → 295.1±26.2 presses/5 min (+41%)p<0.05 before vs after100 µg into the ventricle; 1 and 10 µg lacked significance marks.
All reported results & study design →
Methods, dose & source notes

Study of multiple preparations · Dissertation

Table 4 marks within-condition changes from before administration; no verified between-preparation superiority test. Central and systemic behavioral similarities do not directly measure brain penetration or tissue pharmacokinetics. The assays concern behavior and electrical reinforcement, not athlete endurance.

Oleyl-Cortagen versus Cortagen: central and systemic rat assays ↗

Animal research · 2009

Who or what was studied192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Reported finding

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

Oleyl-Cortagen · self-stimulation
+32% in lateral-hypothalamic pedal pressesReported relative increase, not an endurance or strength endpoint.
Cortexin · self-stimulation
+23% in lateral-hypothalamic pedal pressesReported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative.
Cortagen and Cerebrolysin · self-stimulation
No change reported in pedal-press frequencyAt the systemic doses in this article; does not contradict the separate central-dose comparisons.
All reported results & study design →
Methods, dose & source notes

Study of multiple preparations · Original journal article

Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin ↗

These highlights cover selected studies. Open a source for its methods, reported doses and full context.

Compound class
Lipid-modified peptide
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human intervention recovered.

Study methods

Lateral-hypothalamic self-stimulation and behavior, with distinct systemic and intracerebroventricular experiments.

Independent replication

Independent replication is not established in the linked sources.

Source access

Original sources and the exact review scope are linked below.

Safety evidence

The linked experiments do not establish a safe human performance regimen.

Open a topic for the evidence assessment.

More findings, background and history
EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Authenticate the signed institute original and protocol; reconcile group denominators, background treatment and translation. Independent replication and current-product equivalence remain unverified.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.

Browse original study records ↗
03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2015 · Oleyl-Cortagen versus Cortagen: central and systemic rat assaysOleyl-Cortagen · central self-stimulation: 159.7±16.2 → 199.1±19.1 presses/5 min (+25%)
2015Animal / experimentalRussian source · see review scope

Oleyl-Cortagen versus Cortagen: central and systemic rat assays

Oleyl-Ala–Glu–Asp–Pro is lipid-modified Cortagen. Cortexin and Cerebrolysin were separate tissue peptide comparators. · Dissertation

Format: Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable · Reviewed: Reported methods, results and evidence limitations

I. M. Voeyikov · Kirov Military Medical Academy dissertation author abstract

In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.

Findings, study figures and available tables

Reported findings and study design

In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.

496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison

Dose, route and schedule

Central experiments: 1, 10 or 100 µg into a lateral ventricle, 5–10 minutes before testing. Systemic methods list Cortagen and Oleyl-Cortagen at 0.1 mg/kg intraperitoneally, Cortexin and Cerebrolysin at 1 mg/kg; saline control.

Protocol source ↗ · Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable

Reported findings and study figures · Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable
MeasureResultComparison, timing and statistics
Oleyl-Cortagen · central self-stimulation159.7±16.2 → 199.1±19.1 presses/5 min (+25%)1 µg into the ventricle; 10 and 100 µg produced +19% and +6% without significance marks. · p<0.05 before vs after at 1 µg
Cortagen · central self-stimulation208.0±26.7 → 270.4±26.4 presses/5 min (+30%)100 µg into the ventricle; lower doses lacked a significance mark. · p<0.05 before vs after
Cortexin · central self-stimulation209.3±22.9 → 295.1±26.2 presses/5 min (+41%)100 µg into the ventricle; 1 and 10 µg lacked significance marks. · p<0.05 before vs after
Cerebrolysin · central self-stimulation220.8±21.2 → 280.2±14.2 presses/5 min (+27%)10 µg into the ventricle; 1 and 100 µg lacked significance marks. · p<0.05 before vs after
Anxiety-related behaviorOleyl-Cortagen’s central maze response was described as weaker than Cortagen’sThe direction and magnitude depend on assay and dose; lipidation did not improve every endpoint.
Author abstract Table 4 · lateral-hypothalamic self-stimulation
Author abstract Table 4 · lateral-hypothalamic self-stimulation
Preparation, central doseBefore (presses/5 min)After (presses/5 min)After (% of before)Mismatch coefficient before → after
Saline175.5±18.1170.7±17.498±100.59±0.05 → 0.57±0.05
Cortexin 1 µg161.0±15.9150.2±25.193±170.54±0.06 → 0.64±0.04
Cortexin 10 µg193.2±18.8204.0±22.2106±110.55±0.05 → 0.55±0.06
Cortexin 100 µg209.3±22.9295.1±26.2*141±90.54±0.04 → 0.45±0.05
Cerebrolysin 1 µg184.0±26.7208.8±21.5114±90.58±0.06 → 0.45±0.05
Cerebrolysin 10 µg220.8±21.2280.2±14.2*127±50.56±0.03 → 0.35±0.02
Cerebrolysin 100 µg239.2±15.6270.5±19.3113±70.55±0.04 → 0.46±0.05
Cortagen 1 µg159.0±18.1171.2±20.4108±100.48±0.03 → 0.49±0.02
Cortagen 10 µg189.6±28.1226.1±29.6119±110.47±0.05 → 0.47±0.04
Cortagen 100 µg208.0±26.7270.4±26.4*130±90.47±0.03 → 0.38±0.04
Oleyl-Cortagen 1 µg159.7±16.2199.1±19.1*125±70.61±0.07 → 0.50±0.04
Oleyl-Cortagen 10 µg191.6±25.0228.0±16.1119±110.60±0.05 → 0.39±0.06
Oleyl-Cortagen 100 µg207.6±13.0220.0±17.7106±40.58±0.04 → 0.38±0.03

Asterisk: p<0.05 versus the same condition before dosing. Percentages and mismatch coefficients are as transcribed; original scan and exact arm denominators were not recovered.

Behavioral effects differed by route, dose and test. The low central dose had an effect in this assay; it does not establish systemic exposure, human dosing or superiority in other outcomes.

Source for the extracted data ↗ · Checked 2026-11-08

Population / setting
496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison
What was checked
Original author-abstract transcription with methods and Table 4; original full dissertation scan unavailable
Limitations & review scope
  • Table 4 marks within-condition changes from before administration; no verified between-preparation superiority test.
  • Central and systemic behavioral similarities do not directly measure brain penetration or tissue pharmacokinetics.
  • The assays concern behavior and electrical reinforcement, not athlete endurance.

Source checked 2026-11-08. See the review scope above for the material assessed.

Read the source ↗
2009 · Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and CortexinOleyl-Cortagen · self-stimulation: +32% in lateral-hypothalamic pedal presses
2009Animal / experimentalFull text available

Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin

· Original journal article

Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations

P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

Findings, study figures and available tables

Reported findings and study design

Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.

192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery

Dose, route and schedule

Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.

Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered

Reported findings and study figures · Publisher full-text methods and results narrative; original PDF tables not recovered
MeasureResultComparison, timing and statistics
Oleyl-Cortagen · self-stimulation+32% in lateral-hypothalamic pedal pressesReported relative increase, not an endurance or strength endpoint.
Cortexin · self-stimulation+23% in lateral-hypothalamic pedal pressesReported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative.
Cortagen and Cerebrolysin · self-stimulationNo change reported in pedal-press frequencyAt the systemic doses in this article; does not contradict the separate central-dose comparisons.
Open-field behaviorOleyl-Cortagen increased horizontal and vertical movement but halved hole explorationCortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
Noopept, Semax, Selank and Dilept · vertical activityReduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
Porsolt immobilityLower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.
Deltaran · groomingGrooming reactions increasedThe report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP.

Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.

Source for the extracted data ↗ · Checked 2026-11-08

Population / setting
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
What was checked
Publisher full-text methods and results narrative; original PDF tables not recovered
Limitations & review scope
  • Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
  • Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
  • The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.

Source checked 2026-11-08. See the review scope above for the material assessed.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Cerebrolysin research ↗

2 shared source records

Cortagen research ↗

2 shared source records

Cortexin research ↗

2 shared source records

Dilept research ↗

1 shared source record

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗